Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction—DAPA-STEMI Trial - Ortega-Paz, Luis; Laudani, Claudio; Sionis, Alessandro; Vidal-Cales, Pablo; Arevalos, Victor; Andrea, Rut; Morr, Carlos Igor; De Diego, Oriol; Ortega, Emilio; Jimenez-Trinidad, Francisco-Rafael; Dantas, Ana Paula; Angiolillo, Dominick J.; et al. (Journal of cardiovascular development and disease, 2025)
Keywords: Biomarkers; Cardiovascular disease; Care and treatment; Chronic illnesses; Collagen; Consent; Dapagliflozin; Design; Dextrose; Diabetes; Ejection fraction; Enrollments; Fibroblasts; Fibrosis; Gadobutrol; Glucose; Heart attack; Heart attacks; Heart failure; Hospitals; left; myocardial fibrosis; myocardial infarction; Patients; Prognosis; sodium–glucose transporter 2 inhibitors; Study Protocol; Transluminal angioplasty; Type 2 diabetes; ventricular function; United States; Spain; heart failure; sodium–glucose transporter 2 inhibitors; left; dapagliflozin; myocardial infarction; ventricular function; ventricular remodeling; extracellular space; cardiac magnetic resonance; myocardial fibrosis; randomized controlled trial